In-depth virological and immunological characterization of HIV-1 cure after CCR5Δ32/Δ32 allogeneic hematopoietic stem cell transplantation.
Jensen BO, Knops E, Cords L, Lübke N, Salgado M, Busman-Sahay K, Estes JD, Huyveneers LEP, Perdomo-Celis F, Wittner M, Gálvez C, Mummert C, Passaes C, Eberhard JM, Münk C, Hauber I, Hauber J, Heger E, De Clercq J, Vandekerckhove L, Bergmann S, Dunay GA, Klein F, Häussinger D, Fischer JC, Nachtkamp K, Timm J, Kaiser R, Harrer T, Luedde T, Nijhuis M, Sáez-Cirión A, Schulze Zur Wiesch J, Wensing AMJ, Martinez-Picado J, Kobbe G.
Jensen BO, et al. Among authors: fischer jc.
Nat Med. 2023 Mar;29(3):583-587. doi: 10.1038/s41591-023-02213-x. Epub 2023 Feb 20.
Nat Med. 2023.
PMID: 36807684
Free PMC article.
Despite scientific evidence originating from two patients published to date that CCR5delta32/delta32 hematopoietic stem cell transplantation (HSCT) can cure human immunodeficiency virus type 1 (HIV-1), the knowledge of immunological and virological correlates of cure is limited. …
Despite scientific evidence originating from two patients published to date that CCR5delta32/delta32 hematopoietic stem cell transplantation …